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Abstract
This short review considers to what extent posttranscriptional steps of gene expression can provide the basis for novel
control mechanisms and procedures in synthetic biology and biotechnology. The term biocircuitry is used here to refer to
functionally connected components comprising DNA, RNA or proteins. The review begins with an overview of the diversity of
devices being developed and then considers the challenges presented by trying to engineer more scaled-up systems. While
the engineering of RNA-based and protein-based circuitry poses new challenges, the resulting ‘toolsets’ of components and
novel mechanisms of operation will open up multiple new opportunities for synthetic biology. However, agreed procedures
for standardization will need to be placed at the heart of this expanding field if the full potential benefits are to be realized.
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INSIGHT BOX
Synthetic biology is largely based on transcriptional circuitry, in which promoters, terminators and transcription factor
sites are utilized to build devices and modules. However, biocircuitry can also be engineered using RNA and/or protein
components involved in posttranscriptional steps of gene expression. For example, messenger RNA translation can
be modulated by targeting the 5′untranslated region using RNA-binding proteins, aptamers or aptazymes, whereby
degrons or small ligands can feature in the mechanisms used for regulation. Moreover, an even greater range of
protein structural and functional properties can also potentially be harnessed for use in engineered regulatory
systems. Realization of the full potential of these new directions for synthetic biology will require both further system
development and a concerted effort to improve standardization.
INTRODUCTION
In practical terms, synthetic biology primarily refers to the inten-
sified application of state-of-the-art molecular/cell biology tech-
niques (increasingly enabled through automation and machine
learning [1]) guided by the application of concepts and strate-
gies that are normally associated with engineering [2, 3]. This
distinguishes synthetic biology from discovery bioscience, since
it encompasses principles of design and construction, and is
thereby obliged to address challenges of predictability and stan-
dardization that are more normally associated with engineer-
ing disciplines. The construction of synthetic circuitry is being
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of both fundamental science and biotechnology (e.g. production
of recombinant proteins and metabolites, biosensors, etc.).
In the component ‘toolkits’ currently used in synthetic
biology, there is a predominance of transcriptional parts, more
specifically promoters, transcription factors, transcription factor
modulators (metabolites and other ligands) and transcription
terminators [4–7]. Formulated somewhat differently, synthetic
biology is currently largely about the design, construction and
use of engineered DNA [8]. Transcriptional components and
modules were inevitably the first choices for synthetic biology
because there was a good depth of knowledge of a range of
regulatable transcriptional systems in both prokaryotic and
eukaryotic organisms. However, there are a number of reasons
for exploring options at other points in the gene expression
pathway that occur downstream of transcription. Utilizing solely
regulatable promoters, for example, can, at least in certain host
organisms (including yeast), result in a restricted choice of
independently acting systems [9], a less than optimal dynamic
range, physiologically (metabolically) disruptive activation/sup-
pression mechanisms [10], and limitations in terms of features
such as input–output matching and response times [11]. As a
consequence, up-scaling of the size and complexity of logic
gate circuitry has generally proved challenging (as has been
illustrated by a recent comparison of attempts to build high-
complexity circuits [12]).
Here, we examine the scope for development of posttran-
scriptional biocircuitry, considering the available mechanisms
and layers of control. The term biocircuitry is used to describe
interactive systems that comprise one or more of the biomolec-
ular types DNA, RNA or protein, thus encompassing a much
broader range of components than genetic circuitry. The review
also examines the properties of biocircuitry in terms of parame-
ters such as response times (for example, in yeast, translational
switching can be initiated in less than 10 min [13]), regulatory
dynamic range of regulation, extended scope in terms of diver-
sity of molecular targets, as well as options to create enhanced
systems that combine transcriptional and posttranscriptional
mechanisms in ways that provide improved functionality. The
focus is on Saccharomyces cerevisiae because this is a very impor-
tant biotech workhorse that is increasingly a host of choice for
the engineering of genetic circuitry at different levels. At the
same time, it is one of the most tractable and reliable eukaryotic
hosts for biocircuitry construction. These characteristics are, as
we shall see, important in a number of ways for the wider
field. Budding yeast is a good platform for exploring ways to
engineer, implement, and ultimately standardize, posttranscrip-
tional toolkits, whereby lessons learned in the process can be
expected to inform work using other eukaryotic hosts. Synthetic
biology will never achieve (even get close to) the aspired-to
levels of composability, scalability and robustness [14] without
proper standardization (Fig. 1), and we consider the feasibility
of defining standards relevant to posttranscriptional constructs.
However, at the same time, it is essential to be realistic about
the degree to which the noisy analogue circuitry found in living
cells can be (re-) engineered to conform to the behavioural
characteristics typical of electronic circuitry.
COMPONENTS AND MECHANISMS OF
POSTTRANSCRIPTIONAL CONTROL
Recognition of the range of posttranscriptional control mecha-
nisms operating in living organisms initiated with studies per-
formed on Escherichia coli [15–17] but research on eukaryotic
posttranscriptional control soon caught up [18–20], and it was
not long before yeast became a major focus of work in this
area [21]. It has become evident that a number of different
types of posttranscriptional component can be incorporated
into engineered biocircuitry, either individually or in combi-
nations, depending on the required features of the resulting
systems.
The main processes targeted in the posttranscriptional
expression pathway are the translation and degradation of
mRNA. Achieving specificity largely means utilizing high-
affinity control elements in the 5′ or 3′ UTRs, whereby these
can be targeted either by RNA-binding proteins (RBPs, usually
acting as repressors) or by aptamers, ligands or potentially
non-coding RNAs. As we shall see, a highly desirable (and
often essential) design feature here is that the activity of
such control elements needs to be regulatable. In the context
of practical utilization, this review considers the potential
for these parts to be incorporated into a usable toolbox for
engineering biocircuitry according to principles of predictable
construction and functionality. In order to provide a more
comprehensive picture of the state of current research on
posttranscriptional devices in yeast, this review not only
describes posttranscriptional devices that have already been
described in the literature, but also considers potential new
developments.
RNA-BINDING PROTEINS
One approach to modulating the functionality of target mRNAs
is to use RBPs. One potential advantage of pursuing this
approach is that there is both an abundance, and a rich
variety, of RBPs in living cells [22]. They play important roles
in multiple cellular processes, including transcription, splicing,
5′capping, polyadenylation, RNA transport, mRNA translation
and degradation. Recent experimental and bioinformatic
advances have provided us with an enhanced overview of the
multiplicity of structure and function of the RBP families [23,
24]. However, certain characteristics are generally required of
an RBP if it is to be a candidate for use as a component of
an engineered regulatory device. Most importantly, it needs
to be capable of binding with relatively high affinity to a
specific RNA structural element, in order to minimize off-target
functionality. Moreover, its binding activity needs to be subject
to regulation, ideally manifesting an affinity (or intracellular
abundance) that can be modulated over an appropriate range
with suitable ‘switching’ kinetics. Regulatability of affinity is
intrinsic to only a minority of naturally evolved RBPs, and is
therefore frequently likely to have to be engineered into the
system.
This issue was exemplified early on by the iron regulatory
protein, which is naturally found in different versions in var-
ious higher eukaryotes. For example, human IRP1 has a very
high affinity for the iron-responsive element (IRE) at low iron
concentrations, so that the complex between the two strongly
inhibits translation via the 5′ UTRs of the ferritin and erythroid
5-aminolevulinic acid synthase mRNAs [25, 26]. The IRP–IRE
binding affinity is reduced 50–100-fold at higher iron concen-
trations and this is the basis for iron-concentration-dependent
translational regulation in mammalian cells. However, such iron-
dependent regulation is not readily achievable in the yeast cyto-
plasm, and thus reconstruction of IRP-dependent translational
regulation in S. cerevisiae was originally brought about by means
of transcriptional regulation of IRP production [27]. A similar
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Figure 1. Can synthetic biology become more like a traditional engineering exercise? The upper part of the illustration shows key features that need to be optimized
through application of the engineering design cycle. Standardization according to agreed protocols should be incorporated into the engineering of components, devices
and modules. This enhances composability, scalability and robustness, which matter particularly in relation to larger, more complex, biocircuitry. However, the molecular
interactions underlying cellular biocircuitry have not evolved to behave like electronic circuitry and researchers in this field need to address multiple challenges related
to this fact.
proteins (spliceosomal human U1A protein and bacteriophage
MS2 coat protein) to act as translational repressors in yeast [28].
This established the principle that any high-affinity RBP can, at
least theoretically, be repurposed as a regulatable translational
repressor if appropriately targeted to an mRNA.
As we have seen, earlier demonstrations of translational reg-
ulation exerted via RNA-binding proteins involved modulation
of production of these repressors via regulatable promoters.
However, a key objective at this stage of the field’s develop-
ment is to explore how modulation of the binding of selected
RNA-binding proteins can be achieved via posttranscriptional
mechanisms, so that de novo engineering of a regulatory device
can be rendered independent of transcriptional control (see
examples in Fig. 2). One potential strategy is to make the chosen
RBP subject to conditional degradation. A number of condi-
tional degron systems have been developed in recent years [29].
Temperature-sensitive degrons were initially employed in yeast
predominantly for generating conditional knockouts [30], but
they are also of potential interest as fusion components that ren-
der RNA-binding protein activity subject to temperature shifts.
The target protein is fused at the C-terminal end of a cassette
of the form: ubiquitin-Arg-temperature-sensitive dihydrofolate
reductase (ts-DHFR).
The use of a temperature shift to induce derepression of
a target mRNA will not always be desirable. However, recent
research has seen the development of a number of alterna-
tives. In chemically modulated degron systems, small molecules
control degron stability. Plant-derived auxin-inducible degron
(AID) systems have undergone a number of rounds of develop-
ment to improve the dynamic range of induction by suppressing
auxin-independent degradation of the AID fusion [31, 32]. In an
improved auxin response transcription factor (ARF)-AID system,
the AID-interacting domain of ARF called PBI binds to AID to
prevent association of the auxin-receptor F-box protein TIR1
with AID, thus preventing auxin-independent degradation by
the ubiquitin-mediated proteasomal pathway. In the presence
of auxin, on the other hand, TIR1 binding to AID is enabled, thus
promoting dissociation of ARF, leading to ubiquitination and
proteasome-mediated degradation of the AID-tagged protein.
Alternatively, the small molecule associated shutoff (SMASh)
system, in which the target protein is tagged (at either terminus)
by the HCV NS3 protease together with a degron, has also been
tested in yeast. The protease removes itself and the degron
from the newly synthesized protein unless an inhibitor such as
asunaprevir is added [33]. In contrast, photosensitive degron sys-
tems are, in principle, capable of obviating the need for adding
small molecule inducers to cell cultures. For example, the light
oxygen voltage 2 domain of phototropin from Arabidopsis thaliana
has been fused to degrons in such a way as to render access to
the degron (and thus activation of protein degradation) subject
to (blue light) irradiation [34, 35].
The above consideration of degron systems, while not
exhaustive, serves to illustrate that there are options for
engineering RBPs that can be regulated via modulation of
protein degradation rates. In principle (although not necessarily
always in practice), the activity of any type of RNA-binding
protein, including those possessing enzyme activity, could be
regulated in this manner. For example, future research might
reveal whether the cleavage of AGNN-tetraloop-containing
RNA elements by the yeast RNase III enzyme Rntp1 [36] can
be made subject to degron-mediated modulation (aptamer-
dependent control has also been reported for RNase III
[37]). Overall, given ongoing progress in identifying novel
types of RBP, we can see that there is growing potential for
constructing a diverse set of independently acting devices
that can be regulated at the protein level. At the same time,
it is important to be aware that the degradation properties
of any newly engineered fusion between a target protein
and a degron are currently not predictable. Thus, variable
amounts of optimization work may be necessary in order to
achieve satisfactory regulatory characteristics. The design of
synthetic RNA-binding domains that can be implemented in
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Figure 2. Designs for posttranscriptional devices. Examples of designs for posttranscriptional regulatory/control mechanisms suitable for use in yeast. These include
naturally evolved, as well as de novo engineered, components. In both cases, a genomic construct is transcribed from a constitutive promoter (illustrated here only for
the degron fusion construct in panel A). In one scenario (A), a degron can be activated (via the input of either a chemical ligand or light) to induce degradation of the
encoded repressor-degron fusion protein, resulting in no output. In the absence of degron activation, a functional (non-degraded) degron-repressor fusion protein is
generated. In the second example (B), the ligand input inhibits translation of the repressor ORF by binding to an aptamer, thus giving no output. Therefore, in both cases,
a positive input (of a ligand or of light) is inverted in terms of the availability of functional repressor protein (the output), an input/output relation that is represented
as a NOT gate (see International Electrotechnical Commission symbol in the orange box). Of course, the regulated ORF need not encode a repressor protein.
CONTROL MEDIATED VIA CIS-ACTING RNA
ELEMENTS
An alternative strategy to using a protein repressor to modulate
target gene (mRNA) expression is to utilize cis-acting RNA
elements that are controlled by other mechanisms. A number
of such elements that have evolved naturally in yeast can be
co-opted into new types of regulatory circuit. For example,
the complex 5′UTR of the yeast transcriptional activator gene
GCN4 has been coupled to a recombinant reading frame to
enable starvation-induced synthesis of the encoded product [39].
However, it has become evident that a diverse range of systems
(with favourably engineered properties) can be more readily
built by incorporating exogenous regulatable cis-acting RNA
elements into the UTRs of the target mRNA (see, for example,
Fig. 2). Considerable progress has been made in the use of cis-
acting RNA aptamers as the basis for riboswitch functionality in
S. cerevisiae. Following on from the demonstration of aptamer-
based ligand-dependent regulation in mammalian cells [40],
inducible translational regulation of the yeast cell cycle was
achieved by inserting a tetramethylrosamine-binding aptamer
into the 5′UTR of CLB2 [41]. Tetracycline-aptamer-mediated
regulation was also found to work effectively in yeast, either
by blocking the scanning ribosome when targeted to the 5′UTR
[42] or by inhibiting pre-mRNA splicing when targeted to the 5′
splice site of introns inserted into the early part of a reading
frame [43]. Further natural/synthetic riboswitches have been
characterized in yeast and in other organisms [44].
The most popular approach has been to introduce so-
called aptazyme combinations of a self-cleaving ribozyme
plus a ligand- (e.g. tetracycline-, theophylline- or neomycin-
) binding aptamer into the 3′ or 5′ UTR of a targeted reading
frame, rendering mRNA degradation ligand-dependent [45–
48]. Published reports have so far indicated that engineered
aptazyme systems in yeast can manifest dynamic ranges for
ligand-dependent switching of up to 25-fold [47]. Additionally, it
has been shown that chemical genetics can be combined with
genetic selection techniques to extend the diversity of functional
small molecule ligand pairings with synthetic ribozymes in E. coli
[49], suggesting that similar approaches could be incorporated
into the engineering of aptazyme systems in yeast. Overall,
we can expect to observe a growing landscape of synthetic
riboswitch-based regulatory systems in this host organism.
The above suggests that it should also be possible to engineer
(via a cis-acting aptamer) ligand-dependent regulation into an
RBP-encoding mRNA. Regulatory signal inversion would then
apply to the production of an active repressor protein (i.e. in
terms of the relationship between the ligand or light input and
the production of active RBP; Fig. 2). If this device is then coupled
to translational inhibition of a downstream target mRNA, the
combination of two inhibitory mechanisms would yield, overall,
a positive induction module (that can act like a buffered switch;
Fig. 3). An alternative architecture, in which RBP production
is controlled by a conditional degron instead of a cis-acting
aptamer, would manifest the same functionality. Moreover,
direct aptamer-dependent regulation of a whole range of target
mRNA ORFs is possible. Finally, considering potential future
work in broader terms, the design of aptamer-based systems is
likely to benefit increasingly from computational methods [50].
CONTROL MEDIATED VIA TRANS-ACTING
RNA ELEMENTS?
Intermolecular nucleic acid base-pairing can provide both speci-
ficity and high affinity as the basis for precise targeting. Noncod-
ing RNAs, and the proteins that interact with them, perform mul-
tiple roles in S. cerevisiae [51]. However, natural microRNAs, which
in other organisms guide Argonaute proteins to the 3′UTRs of






/ib/article/13/8/210/6322816 by guest on 29 O
ctober 2021
214 Integrative Biology, 2021, Vol. 13, No. 8
Figure 3. Posttranscriptional logic gate designs based on components described in this review. All regulatory operations are fulfilled at posttranscriptional steps
(here involving mRNA translation). Two illustrative scenarios are shown. (A) Placing aptamer-regulated repressor synthesis in series with repressor-regulated reporter
synthesis creates two NOT gates in series, equivalent to a buffered switching module. (B) Targeting two distinct ligand-dependent aptamer switches into one 5′UTR
yields a NOR gate, whereby each input is equivalent to the presence of one ligand molecule. The aptamers can be replaced by aptazymes.
this has so far limited the options for using ncRNAs as parts of
engineered circuits compared to plants, animals and viruses [53].
Currently, the most scalable approach to engineering higher
order logic gate circuit size and complexity seems to be a largely
transcriptional platform involving the use of gRNA-dCas9-Mxi1
complexes in yeast [12]. A major reason for the relatively low
signal degradation observed with this approach is likely to be
the combination of high specificity and high intermolecular
affinities of the system components, coupled to the high tran-
scriptional repression efficacy of dCas9 (whereby Mxi1 is not
essential for transcriptional repression in yeast). The effective-
ness of this approach demonstrates that there are advantages
in using nucleic-acid-interaction-based targeting. At the same
time, there are also intrinsic challenges in CRISPR-based strate-
gies [54], and regulatable promoters will need to drive gRNA
synthesis at an entry point into the circuitry. Moreover, since
this is a transcriptional strategy, we are obliged to ask whether
a CRISPR-based system could be targeted to mRNA instead.
Recent work with human cell lines has shown that Cas13d
endonucleases can be targeted by gRNAs to mRNAs [55], or
alternatively that Cas6/Cas13 endonucleases can be targeted
to short RNA motifs [56]. We will have to see whether future
work generates a substantially posttranscriptional CRISPR-based
biocircuitry engineering platform that is applicable to yeast.
PROTEIN-BASED BIOCIRCUITRY
This review has so far focused predominantly on how the
structure of RNA elements can be engineered in order to
create new dynamic functionalities within the cell. RNA-binding
proteins can feature in such biocircuitry designs, influencing
RNA activities via mechanisms including the modulation of
endonuclease cleavage and of translation initiation. However,
there are early indications that the full canvas of protein
structures and functional capabilities might be exploited to
create and implement a substantially larger landscape of
protein-based biocircuitry designs [57]. The most exciting aspect
here, of course, is the immense diversity of (high-specificity)
interactions and functions that nature has demonstrated can
be programmed into proteins. At the same time, this structural
complexity and flexibility makes precision protein engineering
challenging, especially if the aim is to build circuits comprising
different interacting protein components. It is interesting to
compare the challenges associated with the engineering of
(single-stranded) RNA-based biocircuitry, in which the additional
degrees of structural and functional complexity relative to
(double-stranded) DNA make available distinct mechanisms
of action that include inhibitory folded structures, ligand-
dependent restructuring, catalysis (cleavage) and sequence-
dependent modulation of interactions with ribosomes (and
associated factors). Engineering protein circuitry offers an
even wider range of capabilities related to molecular binding
specificities, conformational adaptability, signalling, transport
and catalysis, but generally requires a shift to a very high
level of complexity and difficulty in terms of design and
implementation.
ANALOGUE VERSUS DIGITAL RESPONSES
Naturally evolved regulatory devices generally manifest ana-
logue responses to changes in the concentrations of their effec-
tors, whether these are proteins, metabolites or chemical lig-
ands. In other words, the degree of activation or suppression
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effector concentrations. A more digital type of response can be
observed if the regulatory device shows ultrasensitivity, often
reflected in a high Hill coefficient for binding of the effec-
tor molecule [11, 58]. This applies both to RNA and DNA tar-
gets, and therefore more digital-type behaviour can, at least to
some extent, be engineered into posttranscriptional devices. One
means of (partially) achieving this is to modify the effector (for
example, a repressor protein) or the binding target (for example,
an RNA aptamer) in order to increase the Hill coefficient for
binding. On the other hand, it has been suggested that the steps
needed to ‘digitize’ biocircuitry behaviour can create unaccept-
ably high costs in terms of operational energy efficiency [59]. The
imprecision created by system noise represents a related prob-
lem. Noise suppression, for example via measures that minimize
cell-to-cell heterogeneity, generally requires additional energy
expenditure.
COMPOSABILITY AND SCALABILITY
Precision in the rational engineering of any new system relies
on the accurate quantitative characterization of the compo-
nents that are designed into that system [2, 60]. This is the
basis for achieving the composability, scalability and robustness
that are still largely missing from the synthetic biology field.
Indeed, there has been increasing awareness that the lack of
proper standardization is hampering the progress of biological
engineering activities. Significant initial steps have been made
towards satisfying the requirements for achieving predictable
gene expression outcomes from synthetic DNA circuitry in bac-
terial hosts [61]. Such efforts have been underpinned by a variety
of assembly frameworks and strategies, including the Interna-
tional Open Facility Advancing Biotechnology (BIOFAB) and the
BioBricks restriction enzyme assembly standard [8, 62], Gib-
son Assembly, Golden Gate, Modular Overlap-Directed Assembly
with Linkers (MODAL), Standard European Vector Architecture
(SEVA [63]) and others [64]. However, looking at the bigger picture,
standardization for DNA-based components and circuits is not
widely applied to the variety of hosts in use at the present time
[65], and is very limited for other biomolecular parts and sys-
tems involving RNA and proteins. Enabling the truly predictable
engineering of biological systems will require the investment of
considerable time and energy into standardization at multiple
levels, including workflows, system descriptions, measurement
techniques, international systems of units and data sharing
(Fig. 1 [60, 66–71]).
It is self-evident that the presence of suitable abundance
levels of posttranscriptional components, whether these be
riboswitch-containing mRNAs or RNA-binding proteins, relies
upon transcription. Stable rates of synthesis of these entities can
be maintained using constitutive promoters. An important step
here is to choose promoters that manifest appropriate values
for the transcription rate and transcription stochasticity. A
recent study of engineered expression constructs in S. cerevisiae
has illustrated how we can quantitate (and optimize) both
the average value, and the variation, of the copy number of
mRNA molecules per cell [72]. Both smFISH [72] and single-
cell RNAseq [73] can be used to determine mRNA-copy-per-cell
distributions across cell populations. This type of information is
essential for allowing us to balance an optimal dynamic range
of posttranscriptional regulation as exercised on each mRNA
molecule against the potentially disadvantageous effects of cell-
to-cell variation in mRNA copy number. There is a temptation to
focus on the maximization of the transcription rate in order to
reduce the level of mRNA copy number noise, but this will not
necessarily result in a dynamic range of operation of a regulatory
mechanism that matches the intended functionality. This can
be illustrated by considering the use of a strong promoter to
drive transcription of a degron:RNA-binding protein expression
construct that will form part of a regulatory circuit. The high
transcription rate will help to suppress gene expression noise,
but it may also increase the lower limit (base level) of the
degron-mediated regulatory range to a level that results in
only partial activation of translation of the mRNA targeted by
the RNA-binding protein (Fig. 3). These considerations mirror
the challenges inherent in input–output tuning for biocircuitry
dependent on transcriptional regulation (11), and can be
addressed in analogous ways. Computational modelling can
help in developing strategies for achieving the right balance in
terms of the abundance/activities of all components.
Having selected the constitutive transcription platform
used to generate the posttranscriptional components that
will build the required biocircuitry (where appropriate, by
fine-tuning a synthetic promoter [4, 5, 7]), the next step is
to optimize the dynamic range of the regulatory mechanism
operating at the mRNA level. Consider an example in which a
ligand-dependent aptamer or aptazyme has been engineered
into the 5′UTR of an RNA-binding-protein-encoding reading
frame (Fig. 3). The dynamic range of the ligand-dependent
modulation of the aptamer/aptazyme can be optimized by
modifying the aptamer/aptazyme structure [41–44]. The priority
will likely be to measure the full extent of the dynamic range
of aptamer/aptazyme-mediated regulation in terms of the
intracellular RNA-binding protein abundance values. This can be
achieved using quantitative mass spectrometry, benchmarked
by incorporating peptide standards into the cell extract samples
[74, 75]. However, in the interests of pursuing a more readily
accessible set of procedures for standardization (see next
section), it makes sense to replace the RNA-binding protein
with a reporter gene encoding a high-intensity fluorescence
protein such as yEGFP. In this way, it becomes feasible to
define, at least partially, the profile of any such 5′UTR-mediated
posttranscriptional regulatory system in terms of fold-changes
in the fluorescence output of yeast cells at different degrees of
activation of the aptazyme mechanism.
STANDARDIZATION
There has been a substantial amount of work published on the
standardization of design protocols and representation [76–80]
as well as (automated) workflows for the assembly of DNA cir-
cuitry [81, 82]. In contrast, the development of system character-
ization protocols and ‘data sheets’ has lagged behind. Returning
to the question of the value of standardizing the characteriza-
tion of system performance using fluorescence reporters, this
approach can of course only be upheld if the conditions under
which that standardization is performed are strictly defined, and
strictly adhered to, by the wider community. Ideally, the starting
point should be a specific (genomic) construct in a defined strain,
thus avoiding the excessive cell-to-cell heterogeneity in gene
expression associated with variations in plasmid copy numbers.
An engineered strain should be grown under a standardized set
of conditions, and the gene expression output should be mea-
sured following standard procedures using defined techniques.
The synthetic biology community has yet to agree on a uni-
versally applicable set of standards for system characterization.
This is unfortunate, since the absence of agreement on standard-
ization is problematic in two ways. First, it holds back progress in
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Figure 4. ‘Dual-track’ standardization data acquisition for posttranscriptional circuitry. The strategy proposed here is for the creator of a novel system (and/or
collaborators) to perform both a detailed multi-parameter characterization that yields precise technical specifications and a parallel, less-detailed characterization that
focuses on a shallower level of assessment, for example using solely reporter fluorescence profiles. Thus a ‘data sheet’ could be generated for the posttranscriptional
device or module that encapsulates both the detailed and the less-detailed system descriptions. This would then enable other users to perform (routine) checks on
key system behaviour parameters using relatively simple and time-saving techniques (automated, for example, via a plate reader) without having to repeat the more
detailed (and time-consuming) characterization procedures.
that follows predictable behavioural patterns. Second, the lack
of standardization acts as a barrier to the incorporation of engi-
neering principles that would otherwise facilitate the realization
of valuable biotechnological projects. A key challenge is there-
fore to formulate widely acceptable proposals for international
standardization procedures and protocols.
In the context of what has been considered in this review,
the initial standardization process could include characteriza-
tion of the regulatory device (e.g. a 5′UTR-aptazyme-controlled
mRNA) using techniques (including those mentioned above) that
quantitate the intracellular molecular abundance of mRNA and
protein. This could be accompanied by parallel measurements
(using a plate reader and a flow cytometer) of the fluorescence
output of a version of the genomic construct under investigation
that encodes a fluorescence-reporter reading frame. Moreover, it
has been demonstrated that the use of independent calibrants
and standardized protocols in fluorescence measurements on
cells leads to major improvements in precision [83, 84]. Overall,
different combinations of the quantitative techniques outlined
above could be applied depending on the degrees of accuracy and
precision that researchers aspire to (Fig. 4).
A further step towards an ultimate level of standardization
would be to involve computational modelling of the relevant
synthesis and degradation rates in different system states so
as to define the kinetic basis of the measured steady-state
abundance values. This would need to include, for example,
values for translation initiation events per second (TIPS or TIS−1)
or polypeptides completed per second (PCPS or PCS−1) for the
output protein (generated from the ‘receiver’ mRNA), as the
posttranscriptional parallel to measurements of polymerases
per second (PoPS (8)). The resulting data can be used to create
a standardized quantitative profile and time course of the tem-
poral properties of any activation or suppression process. Such
an approach is also of value in the context of incorporating infor-
mation about system stochasticity and cell-to-cell heterogeneity
into the standardization of engineered biosystems.
STOCHASTICITY, RETROACTIVITY AND
ORTHOGONALITY
Up to now, biosystem data sheets have generally featured
population-average values for any given engineered device
or module. However, since noise is an intrinsic property of
biological systems, there is a strong argument for including
at least some stochasticity data in any standard system
description. At a minimum, it would be advisable to conduct
flow cytometry analysis of the cell-to-cell heterogeneity of gene
expression outputs. Such data are important for developing
an understanding of the noise intrinsic to the operation of
engineered biocircuitry across the cells in a host-organism
population. They are also valuable for any researcher wishing
to ‘tune’ the stochasticity characteristics of such biocircuitry.
It has been observed that the noise associated with a given
promoter can be modulated independently of the mean rate of
transcription that it drives in the cell [85, 86]. Other work then
showed that gene expression noise can also be modulated at
the translation level in yeast by modifying the structure of the
5′UTR [72]. Moreover, the incorporation of negative feedback can
be utilized to help control, and buffer, gene expression noise [87].
Given the different ways in which the inherent variability of gene
expression characteristics can influence system performance
and population fitness [88], the inclusion of at least basic
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The dynamic and steady-state characteristics of interactions
between devices/modules can also be affected by retroactivity
[89–92]. This term refers to the effect of modulatory interac-
tions of a molecule with a downstream device/module on the
availability of that molecule to the upstream device/module that
generates it. Reference to Figure 3A provides an example as to
how certain features of posttranscriptional regulatory mecha-
nisms deserve special consideration in terms of vulnerability
to retroactivity effects. The repressor protein generated by the
upstream device may need to bind to a high-affinity binding site
on multiple copies of the downstream target mRNA. Particular
consideration will therefore need to be given to ensuring that
an optimal (steady-state) ratio of repressor molecules to mRNA
target molecules is maintained in the cell. This should normally
be achievable through adjustments of the constitutive tran-
scription rates for the repressor-encoding and reporter-encoding
genes and of the repressor affinity for its mRNA binding site.
Overall, the consequences of restricted levels of retroactivity in
circuitry of this kind designed to perform as steady-state regula-
tory systems are likely to be of limited significance compared to
the impact of retroactivity that undermines important dynamic
features of, for example, signalling systems.
Ideally, the synthetic biologist would prefer to isolate
biomolecular activities encoded by engineered biocircuitry as far
as possible from the cell environment. A high degree of isolation
is desired, although not necessarily always achievable, because
it minimizes negative effects both on the viability of the host
organism and on the expected performance of the biocircuitry.
It is also important to recognize that ‘orthogonalization’ may
need to be engineered into a system, both to minimize crosstalk
between separate domains of engineered genetic circuitry, and
to reduce interference between engineered biocircuitry and
components that are endogenous to the host. A good starting
point, certainly in yeast, is to perform genomic integration of
DNA biocircuitry components. This limits the variability of the
copy number of the DNA components compared to that observed
with extra-chromosomal plasmids, and thus narrows variability
in the negative consequences of interactions between host-cell
and engineered biocircuitry. Orthogonality issues have inevitably
been addressed in most detail, and with most success, in
bacterial hosts [93–96]. Progress in yeast has focused primarily on
engineered promoters [4, 97], and considerable work remains to
be done on the orthogonality of posttranscriptional biocircuitry.
CONCLUSIONS
Research performed over the last four decades has taken us
to a point where the construction of a wide range of posttran-
scriptional devices and modules with usable regulatory prop-
erties has become feasible. Although transcriptional processes
are of course required to synthesize the components of these
devices and modules, it is now possible to engineer all of the
regulation at the posttranscriptional level. Most importantly,
the synthesis, functionality or degradation of proteins, and the
functionality or degradation of mRNA can be rendered subject
to inputs that include chemical ligands, light and temperature
changes. By side-stepping the need for regulation to be mediated
via transcription, we can shorten the timescales and change the
characteristics of the responses elicited by such inputs.
In the context of surveying opportunities for the further
development of posttranscriptional systems, this review has
considered both posttranscriptional devices that have already
been built and tested and examples of devices and larger scale
circuitry that could feasibly be engineered in the near future.
However, additional time and effort need to be invested in char-
acterization of posttranscriptional components, and combina-
tions thereof, in order to provide a more accurate picture of the
benefits that can be achieved in terms of performance relative to
transcriptional circuitry. Moreover, there is scope for biocircuitry
built using components at the DNA, RNA and protein levels in
the gene expression pathway to be combined together, and this
approach has considerable potential that remains to be realized.
The use of parallel mechanisms at different levels of the gene
expression pathway can be expected to facilitate optimization
of key system properties.
At this relatively early stage of development of the posttran-
scriptional area of biocircuitry engineering, it would be wise to
incorporate rigorous standardization as a core element of the
research effort. This will greatly accelerate progression towards
predictability in design and in design implementation. There
is an urgent need for agreement on a set of principles and
procedures that will apply to posttranscriptional circuitry, at
least in selected host organisms. This could be established as
part of a broader set of guidelines that, for example, could extend
to include transcriptional regulatory devices. There are strong
arguments (extensive established procedures for genetic manip-
ulation, ease of use etc.) for yeast, particularly S. cerevisiae, to play
a key role in pioneering efforts in this direction. This could grow
in parallel to the developing standardization work being done
with E. coli, and we would hopefully see analogous standardiza-
tion projects developed for other major synthetic biology hosts.
It would also be beneficial to acknowledge formally that cell-
to-cell heterogeneity is an intrinsic feature of living organisms
that influences system performance by incorporating, at least
for microbial hosts, some form of stochasticity/variation data in
(agreed) standardization procedures.
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